RET and medullary thyroid gland carcinoma: However, among patients previously treated with MKIs, baseline plasma profiling revealed coincident secondary RET mutations in addition to the primary documented RET driver that led to trial enrollment in four MTC patients (Supplemental Tables 2 and 4).